Clinical trial · Interventional
FOLFOX4 Combined With Endostar in Patients With Advanced Colorectal Cancer
A Multi-center Study of Folfox4 Combined With Recombinant Human Endostatin(Endostar)in Advanced Colorectal Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
FOLFOX4 plus Avastin has been suggested as firstline regimen for advanced colorectal cancer by NCCN, a new angiogenesis inhibitor, known as Endostar(Recombinant Human Endostatin), prolonged the overall survival, time to progression and improved response rate in metastatic lung cancer in a large phase III clinical trial in china, so we design this trial to evaluate the safty and efficacy of FolFox4 plus Endostar in patients with advanced colorectal cancer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Neoplasms | Colorectal Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Folfox4 plus recombinant human endostatin (Endostar) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Folfox4 plus Endostar
- interventionNames
- Drug: Folfox4 plus recombinant human endostatin (Endostar)
Primary outcomes (1)
- measure
- Time to progression
- timeFrame
- every two cycles
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with histologically or cytologically confirmed metastatic CRC * Measurable disease according to Response Criteria In Solid Tumours (RECIST) * Performance Status 0 - 2 according to ECOG (Eastern Cooperative Oncology Group) Performance Status * Age 18\~75 * Life expectancy \> 3 months * Signed informed consent (IC) * Adequate haematological and biological functions Exclusion Criteria: * Pregnant or lactating women * Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the study drugs * Neuropathy, brain, or leptomeningeal involvement * Treatment with any biologic, cytotoxic, radiation , or hormonal therapy within four weeks. * Clinically relevant coronary artery disease or a history of a myocardial infarction within the last 12 months or high risk/uncontrolled arrhythmia * Uncontrolled significant comorbid conditions and previous radiotherapy
References
Publications (0)
Data not yet available